Hanchor-KY
7827TaiwanBiotechnology and healthcare2026 H1
Hanchor-KY (7827) reported TWD 0.0bn of revenue over the first six months of 2026 (cumulative, Q1–Q2).
These figures run from the start of the financial year. The Taiwan Stock Exchange files income-statement lines cumulatively, so a Q2 filing covers the first six months of 2026 (cumulative, Q1–Q2) — not three months on their own. Balance-sheet lines are the position on the closing date instead. That makes this page not directly comparable with the annual figures on our Korean and Japanese company pages; compare it with another Taiwanese filing covering the same months.
Reported financials
Figures are as filed, in billions of New Taiwan dollars (TWD bn). We do not convert to dollars — an exchange rate would be a number we made up, not one the company reported. Income-statement lines cover the whole period named below; balance-sheet lines are the position on its closing date.
| Period covered (income statement) | 2026 H1 |
|---|---|
| Revenue | 0.0 |
| Operating profit | -0.6 |
| Pre-tax profit | -0.6 |
| Net profit | -0.6 |
| Total assets (at the closing date) | 1.9 |
| Total liabilities | 0.5 |
| Equity | 1.5 |
| Net asset value per share | TWD 9.47 |
Ratios from those figures
Each ratio is computed from the two lines above it. A dash means an input was missing or the denominator was zero — not that the value is zero. Return on equity divides a year-to-date profit by equity at one date, so it is not an annual rate.
| Operating margin | -6,219.5% |
|---|---|
| Net margin | -6,201.8% |
| Equity / assets | 75.4% |
| Liabilities / equity | 0.33 |
| Return on equity (year to date, not annualised) | -40.3% |
These are arithmetic, not judgements. We do not say whether a margin is good or bad, and we do not rank companies against each other.
What the market paid — close on 2026-09-22
A closing price is one moment; the figures above cover a whole period. We put them on the same page because both are filed by the exchange, not because they are measured the same way.
| Closing price | TWD 163 |
|---|---|
| Market value (close × shares outstanding) | TWD 23.0bn |
| Price / earnings | — |
| Price / book | 17.21 |
| Dividend yield | — |
The exchange leaves price / earnings blank for a company with no trailing profit, so a dash there is not a zero.
The company itself
| Shares outstanding | 140,816,408 |
|---|---|
| Paid-in capital | TWD 1.4bn |
| Chair | 劉世高 |
| Company site | www.hanchorbio.com |
Other companies in Biotechnology and healthcare 生技醫療業
61 listed companies file under this classification. Showing 12. See all 61, with the medians for the classification.